Emergent BioSolutions | EBS - Assets


Emergent BioSolutions reported $1.82B in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
ANI Pharmaceuticals USD 1.49B 72.14M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Exelixis USD 2.49B 99.36M Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
Merck USD 129.8B 1.12B Jun/2026
Moderna USD 10.96B 527M Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025